Lanreotide

New to peptides? Start with what are peptides? and how do peptides work?

Overview

Lanreotide is a somatostatin analog in the same family as octreotide, built on the same idea: mimic the body's natural inhibitory hormone somatostatin, but survive long enough in the bloodstream to be useful as a medicine. Where the two drugs differ is less in what they do than in how they are formulated and delivered.

The formulation is the innovation

Lanreotide's modern form is a supersaturated aqueous gel supplied in a prefilled syringe and injected deep under the skin, usually about once a month. There is no polymer microsphere, no reconstitution step, and no intramuscular injection — the peptide itself forms the depot. In practice this makes lanreotide unusually suited to administration in the clinic or, in some settings, by a trained patient or caregiver at home, which is a meaningful quality-of-life difference for a drug taken indefinitely.

What it is used for

Lanreotide occupies two clinical territories. The first is acromegaly, where it suppresses excess growth hormone. The second, and the one that changed how the whole drug class is viewed, is gastroenteropancreatic neuroendocrine tumors, where a landmark randomized trial showed it slowed disease progression rather than merely controlling symptoms.

Like the rest of the somatostatin analogs, lanreotide is an approved prescription medicine used under specialist care — a different category entirely from the unapproved peptides sold online.

How it works

Lanreotide binds somatostatin receptors with a profile similar to octreotide's: strong affinity for SSTR2, weaker affinity for SSTR5, and comparatively little for the remaining subtypes. Activating those receptors produces two distinct kinds of effect.

Antisecretory effects

On pituitary cells, SSTR2 activation suppresses growth hormone release, which lowers circulating IGF-1. On pancreatic and gut cells it suppresses insulin, glucagon, gastrin, and vasoactive intestinal peptide. In hormone-producing tumors this is what quiets the flushing, diarrhea, and other symptoms driven by hormone excess.

Antiproliferative effects

Somatostatin receptors also couple to intracellular signaling that arrests cell-cycle progression and can promote programmed cell death. Many gastroenteropancreatic neuroendocrine tumors express SSTR2 densely, which is why a receptor-targeted drug can act directly on the tumor's growth rather than only on the hormones it releases. This receptor density is also what makes these tumors visible on somatostatin-receptor imaging and treatable with receptor-targeted radionuclide therapy — the same biology used three different ways.

Why the depot matters mechanistically

Somatostatin receptors respond to sustained occupancy. A drug that produces steady levels for a month engages the receptor continuously rather than in peaks and troughs, which is the rationale for depot formulations across this entire class.

Clinical uses & evidence

Acromegaly

In acromegaly, lanreotide autogel controls growth hormone and IGF-1 in a large share of patients and is a standard medical therapy when surgery does not achieve remission or is not appropriate. It also reduces tumor size in some patients and improves the headache, joint pain, soft-tissue swelling, and sweating that characterize the disease. Response is not universal and depends substantially on how strongly the tumor expresses SSTR2.

Neuroendocrine tumors: the CLARINET trial

The pivotal CLARINET trial randomized patients with metastatic, non-functioning enteropancreatic neuroendocrine tumors to lanreotide or placebo. Lanreotide significantly prolonged progression-free survival. The significance of that result is worth spelling out: the patients enrolled did not have hormone-driven symptoms to control, so the benefit could not be explained as symptom relief. It demonstrated an antitumor effect, and it established somatostatin analogs as disease-modifying therapy in this setting rather than supportive care. Practice guidelines were rewritten accordingly.

Carcinoid syndrome

Lanreotide also reduces flushing and diarrhea in patients with functioning tumors and carcinoid syndrome, with evidence supporting both symptom control and reduced need for rescue medication.

How it compares to octreotide

Head-to-head evidence suggests broadly comparable efficacy in acromegaly, with the practical differences lying in formulation, injection route, dosing interval, and administration setting rather than in potency. Choice between them is usually driven by patient circumstances, response, tolerability, and access rather than by a clear superiority argument.

Forms & how it's given

Lanreotide is supplied as a prefilled, ready-to-use syringe containing a long-acting gel, given by deep subcutaneous injection — typically in the upper outer buttock — approximately every four weeks. No mixing or reconstitution is required, and the product is stored refrigerated.

The dose and the interval are both adjustable. Specialists may lengthen the interval for well-controlled patients or shorten it for those with breakthrough symptoms, guided by hormone levels, symptoms, and imaging. In some healthcare systems, patients or caregivers are trained to give the injection at home after initial clinic administration, which reduces the burden of a monthly hospital visit.

We do not publish dosing protocols. Lanreotide dosing is individualized against biochemical monitoring by an endocrinologist or oncologist, and self-directed use is not applicable to a hospital-supplied depot medicine.

Safety & legal status

Lanreotide's safety profile closely mirrors octreotide's, which is expected given the shared mechanism.

• Gastrointestinal effects — diarrhea, abdominal pain, nausea, and flatulence are the most common, usually most pronounced in the first months of treatment.
• Gallstones and biliary sludge develop in a meaningful proportion of patients on long-term therapy because the drug reduces gallbladder emptying. Many cases are asymptomatic and found on routine imaging.
• Blood-sugar changes in either direction, since insulin and glucagon secretion are both suppressed. Glucose monitoring is standard, particularly in patients with diabetes.
• Bradycardia and other conduction effects can occur, more relevant in patients with existing cardiac disease.
• Injection-site reactions including pain, nodules, and induration are common with any depot.
• Vitamin B12 and thyroid function may need periodic checking on long-term therapy.

Legal status

Lanreotide is an FDA-approved, prescription-only medicine dispensed through the regulated supply chain and administered under specialist supervision. It is not available as a research chemical and has no consumer market. As with the rest of this class, it belongs firmly in the approved-medicine tier of our evidence framework.

The somatostatin analogs compared

All three mimic somatostatin, the body's broad "off switch" hormone. What separates them is which receptor subtypes they reach — which in turn decides what each one can treat.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Castinetti F, Saveanu A, Morange I, et al. Lanreotide for the treatment of acromegaly. Adv Ther. 2009. Peer-reviewed study
2. Colao A, Grasso LFS, Giustina A, et al. Acromegaly. Nat Rev Dis Primers. 2019. Peer-reviewed study
3. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014. Peer-reviewed study
4. Caplin ME, Pavel M, Phan AT, et al. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. Endocrine. 2021. Peer-reviewed study
5. Burness CB, Dhillon S, Keam SJ. Lanreotide autogel: a review of its use in the treatment of patients with acromegaly. Drugs. 2014. Peer-reviewed study
6. Saif MW, Parikh R, Ray D, et al.. Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors. J Gastrointest Oncol. 2019. Peer-reviewed study
7. Turner HE, Vadivale A, Keenan J, et al.. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf). 1999. Peer-reviewed study
8. Chanson P, Boerlin V, Ajzenberg C, et al.. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf). 2000. Peer-reviewed study
9. Tutuncu Y, Berker D, Isik S, et al.. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary. 2012. Peer-reviewed study
10. Turner HE, Lindsell DR, Vadivale A, et al.. Differing effects on gall-bladder motility of lanreotide SR and octreotide LAR for treatment of acromegaly. Eur J Endocrinol. 1999. Peer-reviewed study
11. Kiesewetter B, Pflüger FF, Melhorn P, et al.. Long-term experience with octreotide and lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors. Clin Transl Oncol. 2025. Peer-reviewed study
12. Wang L, Chen S, Wu M, et al.. Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases. Sci Rep. 2025. Peer-reviewed study
13. Zhao Y, Tao Y, Zhu Y, et al.. Comparison of somatostatin analogues on glucose metabolism: A systematic review and network Meta-Analysis of randomized controlled trials. Endocrine. 2026. Peer-reviewed study